Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-VIEW
2016-000343-14Phase 4Completed
- Sponsor
- UCB
- Start
- Jul 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of certolizumab pegol in axial spondyloarthritis (axSpA), sponsored by UCB. Primary endpoint: Number of distinct episodes of anterior uveitis flares during the treatment period. Started Jul 2016; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2016-000343-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000343-14.